Statin use prior to ischemic stroke onset is associated with decreased in-hospital mortality

Fundamental and Clinical Pharmacology

Volumn 25, Issue 3, 2011, Pages 388-394

  Hassan, Yahaya ^a   Al Jabi, Samah W ^a,b   Aziz, Noorizan Abd ^a   Looi, Irene ^c   Zyoud, Sa'ed H ^b,d  

^a SCHOOL OF PHARMACEUTICAL SCIENCES   (Malaysia)

^b AN NAJAH NATIONAL UNIVERSITY   (Palestine)

^c HOSPITAL PULAU PINANG   (Malaysia)

^d SCHOOL OF PHYSICS   (Malaysia)

Author keywords

Acute ischemic stroke; In hospital mortality; Statins

Indexed keywords

ATORVASTATIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; BRAIN ISCHEMIA; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DYING; FEMALE; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION; SURVIVAL;

ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; HOSPITAL MORTALITY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MALAYSIA; MALE; MIDDLE AGED; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; RISK FACTORS; STATISTICS, NONPARAMETRIC; STROKE;

EID: 79954598755     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2010.00846.x     Document Type: Article

References (44)

1. Rothwell P.M., Coull A.J., Silver L.E. et al. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories. Lancet (2005) 366 1773-1783.
2. Sacco R.L., Adams R., Albers G. et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke (2006) 37, 577-617.
3. Amarenco P., Labreuche J., Lavallee P., Touboul P.J. Statins in stroke prevention and carotid atherosclerosis-systematic review and up-to-date meta-analysis. Stroke (2004) 35 2902-2909.
4. Baigent C., Keech A., Kearney P.M. et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet (2005) 366 1267-1278.
5. Marti-Fabregas J., Gomis M., Arboix A. et al. Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke (2004) 35 1117-1121.
6. Yoon S.S., Dambrosia J., Chalela J. et al. Rising statin use and effect on ischemic stroke outcome. BMC Med. (2004) 2 4.
7. Hess D.C., Demchuk A.M., Brass L.M., Yatsu F.M. HMG-CoA reductase inhibitors (statins): a promising approach to stroke prevention. Neurology (2000) 54 790-796.
8. Cheung B.M., Lauder I.J., Lau C.P., Kumana C.R. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br. J. Clin. Pharmacol. (2004) 57 640-651.
9. WHO task force on stroke and other cerebrovascular disorders. Recommendations on stroke prevention, diagnosis, and therapy. Stroke (1989) 10 1407-1431.
10. Vaughan C.J., Gotto A.M. Jr. Update on statins: 2003. Circulation (2004) 110 886-892.
11. Hajat C., Dundas R., Stewart J.A. et al. Cerebrovascular risk factors and stroke subtypes: differences between ethnic groups. Stroke (2001) 32 37-42.
12. Pinto A., Tuttolomondo A., Di Raimondo D., Fernandez P., Licata G. Cerebrovascular risk factors and clinical classification of strokes. Semin. Vasc. Med. (2004) 4 287-303.
13. Hunt SA; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J. Am. Coll. Cardiol. (2005) 46, e1-e82.
14. Waring W.S., Jamie H., Leggett G.E. Delayed onset of acute renal failure after significant paracetamol overdose: a case series. Hum. Exp. Toxicol. (2010) 29 63-68.
15. Kernan W.N., Viscoli C.M., Brass L.M. et al. The stroke prognosis instrument II (SPI-II): a clinical prediction instrument for patients with transient ischemia and nondisabling ischemic stroke. Stroke (2000) 31 456-462.
16. Hamidon B., Raymond A.A. Predictors of in-hospital mortality after an acute ischaemic stroke. Neurol. J. Southeast Asia (2003) 8 5-8.
17. Asawavichienjinda T., Boongird P. Cerebrovascular disease in North East Thailand. Neurol. J. Southeast Asia (1998) 3 27-33.
18. Wong K.S. Risk factors for early death in acute ischemic stroke and intracerebral hemorrhage: a prospective hospital-based study in Asia. Asian Acute Stroke Advisory Pane. Stroke (1999) 30 2326-2330.
19. Kimura K., Kazui S., Minematsu K., Yamaguchi T.; Japan Multicenter Stroke Investigators' Collaboration (J-MUSIC). Hospital-based prospective registration of acute ischemic stroke and transient ischemic attack in Japan. J. Stroke Cerebrovasc. Dis. (2004) 13 1-11.
20. Osmani A.H., Durrani R.K., Ara J.. Comparison of outcome in different types of stroke due to cerebral ischemia. J. Coll. Physicians Surg. Pak. (2010) 20 42-46.
21. Dalal P.M., Malik S., Bhattacharjee M. et al. Population-based stroke survey in Mumbai, India: incidence and 28-day case fatality. Neuroepidemiology (2008) 31 254-261.
22. Elkind M.S.V., Flint A.C., Sciacca R.R., Sacco R.L. Lipid-lowering agent use at ischemic stroke onset is associated with decreased mortality. Neurology (2005) 65 253-258.
23. Becker K., Chopp M. Role of statins in the treatment and prevention of stroke introduction. Stroke (2004) 35 2706-2707.
24. Rosenson R.S., Tangney C.C. Antiatherothrombotic properties of statins implications for cardiovascular event reduction. JAMA (1998) 279 1643-1650.
25. Sheehy N., Vaughan C.J., Delanty N. Statins and neuroprotection. Expert. Opin. Invest. Drugs (2001) 10 1847-1853.
26. Vaughan C.J. Prevention of stroke and dementia with statins: effects beyond lipid lowering. Am. J. Cardiol. (2003) 91 23B-29B.
27. Rosenson R.S. Biological basis for statin therapy in stroke prevention. Curr. Opin. Neurol. (2000) 13 57-62.
28. Amarenco P. Hypercholesterolemia, lipid-lowering agents, and the risk for brain infarction. Neurology (2001) 57 S35-S44.
29. Dyker A.G., Weir C.J., Lees K.R. Influence of cholesterol on survival after stroke: retrospective study. BMJ (1997) 314 1584-1588.
30. Vauthey C., de Freitas G.R., van Melle G., Devuyst G., Bogousslavsky J. Better outcome after stroke with higher serum cholesterol levels. Neurology (2000) 54 1944-1948.
31. Ichihara K., Satoh K. Disparity between angiographic regression and clinical event rates with hydrophobic statins. Lancet (2002) 359 2195-2198.
32. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation: a major contributor to stroke in the elderly The Framingham Study. Arch. Intern. Med. (1987) 147 1561-1564.
33. Nedeltchev K., Renz N., Karameshev A. et al. Predictors of early mortality after acute ischemic stroke. Swiss Med. Wkly (2010) 140 254-259.
34. Patti G., Chello M., Candura D. et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of Myocardial Dysrhythmia After cardiac surgery) study. Circulation (2006) 114 1455-1461.
35. Ozaydin M., Varol E., Aslan S.M. et al. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am. J. Cardiol. (2006) 97 1490-1493.
36. Patel A.A., White C.M., Shah S.A., Dale K.M., Kluger J. Coleman CI. The relationship between statin use and atrial fibrillation. Curr. Med. Res. Opin. (2007) 23 1177-1185.
37. Jamrozik K., Broadhurst R.J., Forbes S., Hankey G.J., Anderson C.S. Predictors of death and vascular events in the elderly: the Perth Community Stroke Study. Stroke (2000) 31 863-868.
38. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet (2008) 371 117-125.
39. Grundy S.M., Cleeman J.I., Merz C.N., for the Coordinating Committee of the National Cholesterol Education Program, Endorsed by the National Heart, Lung, and Blood Institute, American College of Cardiology Foundation, and American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation (2004) 110 227-239.
40. Fabjan T.H., Hojs R., Tetickovic E., Balon B.P. Ischaemic stroke - impact of renal dysfunction on in-hospital mortality. Eur. J. Neurol. (2007) 12 1351-1356.
41. Sweileh W.M., Sawalha A.F., Al-Aqad S.M., Zyoud S.H., Al-Jabi S.W. Predictors of in-hospital mortality after a acute stroke: impact of gender. Int. J. Clin. Exp. Med. (2009) 2 41-47.
42. Wanner C., Quaschning T. Dyslipidemia and renal disease: pathogenesis and clinical consequences. Curr. Opin. Nephrol. Hypertens. (2001) 10 195-201.
43. Fried L.F., Orchard T.J., Kasiske B.L. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. (2001) 59 260-269.
44. Amin-Hanjani S., Stagliano N.E., Yamada M., Huang P.L., Liao J.K., Moskowitz M.A. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke (2001) 32 980-986.